Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

Sponsor
Beni-Suef University
Study ID
NCT04871854
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    patients treated with Tocilizumab for Covid-19 infection
  • traditional Covid -19 therapy — DRUG
    patients treated with traditional therapy for Covid-19 infection

Study Details

To compare evaluating Clinical outcomes for patients treated with with or without breast cancer patients comorbidity for sever COVID-19 infection in breast cancer patients versus non cancer patients and evaluating Tocilizumab efficacy versus traditional therapy

Key Dates

Start date
Apr 26, 2021
Status verified
Oct 2022
Primary completion
Jul 26, 2022
Completion
Aug 26, 2022

Study Design

Enrollment
100 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Svere infected Covid-19 control
    Arm one confirmed sever COVID 19 infection admitted to ICU including with or without breast cancer patients comorbidity receive traditional therapy
  • Active Comparator: sever infected Covid -19 pateints study
    Arm two patients with confirmed sever COVID 19 infection admitted to ICU with or without breast cancer patients comorbidity tocilizumab

Primary Outcome Measure

Overall survival (OS) after treatment of Tocilizumab [ Time Frame: 28 days time fram ]

Related Studies